Novo, Veru Partner on Muscle-Sparing Obesity Trial

Combination trials are evaluating oral compounds alongside injectables to address muscle preservation.

Biopharmaceutical innovator Veru Inc. has entered into a strategic clinical supply agreement with Novo Nordisk to support its ongoing Phase 2b PLATEAU trial. This collaboration will investigate a combination therapy designed to protect patients from muscle loss during active weight reduction. Under the agreement, Novo Nordisk will supply Wegovy (semaglutide), the popular once-weekly weight loss injection, to help researchers determine if adding a muscle-building compound can improve overall body composition.

How Are Novo Nordisk and Veru Partnering on the PLATEAU Trial?

Veru remains the sole sponsor of the Phase 2b clinical trial and will fund all development costs, while Novo Nordisk will provide Wegovy at no cost. In exchange, Veru will share clinical data, trial methodologies, and safety updates with Novo Nordisk as the study progresses. This partnership allows both companies to explore whether combining a selective muscle-targeting molecule with a GLP-1 receptor agonist can prevent the loss of lean tissue during weight loss.

What is Enobosarm and How Does It Protect Muscle?

Developed by Veru, enobosarm is an investigational, oral selective androgen receptor modulator (SARM)—a drug designed to build muscle and bone strength without the unwanted side effects on other organs associated with testosterone. Pair this compound with popular semaglutide treatment programs, and the goal is to address one of weight loss's biggest challenges: losing healthy muscle alongside unwanted fat. By selectively targeting androgen receptors in muscle tissue, enobosarm aims to keep patients strong and active as they shed weight.

Why is Preserving Muscle Mass Critical for Older Adults?

Clinical trials show that up to 40% of the weight lost on GLP-1 receptor agonists can come from lean muscle mass rather than fat. For older adults, this loss of vital muscle can worsen sarcopenia (the natural, age-related loss of muscle strength and physical function), which increases the risk of frailty, falls, and joint problems. The PLATEAU trial specifically recruits older participants to see if enobosarm can keep their muscles intact. Patients who are curious about eligibility can check if you qualify for modern clinical weight management assessments online.

What Are the Terms of the Novo-Veru Partnership?

According to Veru's filings with the U.S. Securities and Exchange Commission (SEC), Veru retains full global development and commercialization rights to enobosarm. However, the agreement grants Novo Nordisk a right of first negotiation if Veru decides to license or sell enobosarm for combination therapy in the future. The supply deal does not involve any upfront cash, stock transfers, or licensing fees between the companies, keeping the immediate focus entirely on clinical research.

What is the Future of Combination Weight Loss Treatments?

The PLATEAU trial is a randomized, double-blind, placebo-controlled study evaluating enobosarm in patients who have already lost weight using semaglutide. Researchers will track changes in lean muscle and fat tissue to see if combination therapy is necessary for long-term health. While these findings are still in the early stages, they could eventually reshape how doctors design weight-management plans for older adults. Patients should consult a healthcare professional before altering any clinical treatment plan.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.